Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPN | P05981 | 14/20 | 0.61 |
| ▸ | PLAU | P00749 | 14/20 | 0.61 |
| ▸ | F2 | P00734 | 3/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.57 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.57 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.57 |
| ▸ | F10 | P00742 | 2/20 | 0.55 |
| ▸ | PLAT | P00750 | 2/20 | 0.55 |
| ▸ | PLG | P00747 | 1/20 | 0.55 |
| ▸ | F9 | P00740 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12545751 | 0.80 | F2 (0.65) | HPNPLAUF2PRSS1PRSS2 | |
| SCHEMBL4086777 | 0.78 | MAPT (0.58) | — | |
| SCHEMBL699996 | 0.78 | MAPT (0.58) | — | |
| SCHEMBL4100731 | 0.76 | PLG (0.54) | PLGF9 | |
| SCHEMBL4224686 | 0.76 | F2 (0.74) | PLAUF2PRSS1PRSS2PRSS3 | |
| 4-Methylbenzimidamide SCHEMBL524027 | 0.75 | LMNA (0.59) | PLAUF2PRSS1PRSS2PRSS3 | |
| SCHEMBL21336212 | 0.75 | HSD17B10 (0.60) | HPNPLAUF2PRSS1PRSS2 | |
| SCHEMBL10816340 | 0.75 | MAPT (0.58) | — | |
| SCHEMBL7903320 | 0.74 | F2 (0.71) | PLAUF2PRSS1PRSS2PRSS3 | |
| SCHEMBL13103177 | 0.74 | HSD17B10 (0.58) | HPNPLAUF2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069288-B1 | TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2014-03-26 | — | — | EP | claimed |
| US-8263621-B2 | Tartrate derivatives for use as coagulation factor IXa inhibitors | SANOFI (FR) | 2012-09-11 | — | — | US | claimed |
| US-20090233961-A1 | TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | claimed |
| US-8263621-B2 | Tartrate derivatives for use as coagulation factor IXa inhibitors | SANOFI (FR) | 2012-09-11 | — | — | US | disclosed |
| US-8263621-B2 | Tartrate derivatives for use as coagulation factor IXa inhibitors | SANOFI (FR) | 2012-09-11 | — | — | US | disclosed |
| US-8263621-B2 | Tartrate derivatives for use as coagulation factor IXa inhibitors | SANOFI (FR) | 2012-09-11 | — | — | US | disclosed |
| US-20090233961-A1 | TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233961-A1 | TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233961-A1 | TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | disclosed |
| WO-2008031508-A1 | TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI-AVENTIS (FR) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233961-A1 | TARTRATE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | TFPI, TFPI2, F9 | HPN 476/4885PLAU 74/4885F2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.